Boron neutron capture therapy of the rat 9L gliosarcoma: evaluation of the effects of shark cartilage.
A number of anti-angiogenic substances are now under evaluation, both experimentally and clinically, as potential agents for the treatment of cancer. It has recently been demonstrated that anti-angiogenic agents can increase the therapeutic potential of photon irradiation in a range of tumour models. In the present communication a preliminary assessment is made of the effects of shark cartilage on the response of the rat 9L gliosarcoma to boron neutron capture therapy (BNCT). Shark cartilage was administered orally as an aqueous suspension at a daily dose of approximately 2000 mg kg-1 body weight. The mean survival time of rats receiving no treatment was 20.7 +/- 0.5 days post intracranial tumour implantation. Administration of shark cartilage alone extended the survival time. Two of the rats treated with shark cartilage were healthy and fully active at the end of the evaluation period (43 days post implantation). At autopsy the brain tumours of these animals were a factor of approximately 4 smaller than controls. In a repeat study with shark cartilage alone the survival time was extended by approximately 30%. After boronophenylalanine-mediated BNCT, with or without shark cartilage, the survival time of rats that eventually became moribund was increased by a factor of approximately 2 relative to controls. In both treatment groups approximately 20% of rats were healthy at 1 year after BNCT. There was no evidence of residual tumour at post-mortem. It was concluded that shark cartilage, when given alone, significantly increased the survival time of tumour-bearing rats, presumably owing to an anti-angiogenic effect. However, the survival data suggested that boronophenylalanine-mediated BNCT did not appear to be enhanced by the administration of shark cartilage.
Morris
G M
GM
Research Institute (University of Oxford), Churchill Hospital, UK.
Coderre
J A
JA
Micca
P L
PL
Lombardo
D T
DT
Hopewell
J W
JW
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D016754:Boron Neutron Capture Therapy; D001932:Brain Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000628:therapy; D002356:Cartilage; D018316:Gliosarcoma / Q000473:pathology / Q000532:radiotherapy* / Q000628:therapy; D009368:Neoplasm Transplantation; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D051381:Rats; D011916:Rats, Inbred F344; D012754:Sharks; D015996:Survival Rate; D014020:Tissue Extracts / Q000627:therapeutic use*; D014407:Tumor Cells, Cultured
D020533:Angiogenesis Inhibitors; D011838:Radiation-Sensitizing Agents; D014020:Tissue Extracts